Dr. Naoaki Arima joined CICS in June, 2015, and is working on finding novel pharmacological targets for diabetes. In 2012, he started working in diabetes research group in pharmacology research dept. at Tokyo New Drug Research Laboratories (KOWA Company, Ltd.). He carried out in vivo evaluation using type 2 diabetic animal models and in vitro evaluation using cells, isolated islet and so on. He received his Ph.D. (Pharmaceutical science) at Tohoku University in 2012, where he focused on researching lysophospholipids, especially lysophosphatidic acid (LPA) which attracted attention as a new lipid mediator. He investigated the role in the bone formation of LPA signaling and discovered the new function of LPA in bone formation.